- Home
- EDD vs CADL Comparison
EDD vs CADL Comparison
Compare EDD & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDD | CADL |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.5M | 339.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDD | CADL |
|---|---|---|
| Price | $5.52 | $5.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | 254.3K | ★ 976.9K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.22 | $4.25 |
| 52 Week High | $4.95 | $13.68 |
Technical Indicators
Market Signals| Indicator | EDD | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 52.75 |
| Support Level | $5.47 | $5.45 |
| Resistance Level | $5.55 | $6.14 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 19.57 | 16.73 |
Price Performance
Historical ComparisonAbout EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.